Cargando…
Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report
PURPOSE: Lurasidon is a relatively new, second-generation antipsychotic drug with an interesting receptor profile. It is considered to be safe and has a low risk of side effects. It is a substance with a multi-receptor mechanism of action: it mainly blocks dopaminergic D2 and serotonergic 5-HT2A rec...
Autores principales: | Mielczarek, Zuzanna, Trędzbor, Beata, Piekarska-Bugiel, Katarzyna, Krysta, Krzysztof |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683055/ https://www.ncbi.nlm.nih.gov/pubmed/38034503 http://dx.doi.org/10.5114/ppn.2023.132474 |
Ejemplares similares
-
Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia
por: Mielczarek, Z., et al.
Publicado: (2023) -
The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD
por: Bieś, Rafał, et al.
Publicado: (2023) -
The correlation beteen lifestyle and risk of metabolic syndrome in schizophrenia
por: Krysta, K., et al.
Publicado: (2023) -
Neutropenia with Multiple Antipsychotics Including Dose Dependent Neutropenia with Lurasidone
por: Sood, Shabnam
Publicado: (2017) -
Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
por: Miura, Itaru, et al.
Publicado: (2023)